The NCCN ORP strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. We believe we can achieve this goal by supporting oncology preclinical, translational, and clinical research at NCCN Member Institutions. We recognize the importance of developing and maintaining strong alliances with industry and actively facilitating collaborations between academia and industry drug developers making important scientific strides in the field of oncology. It is NCCN's vision to have the NCCN ORP become a Center for Excellence in the United States for providing outstanding research and research services.
The NCCN Oncology Research Program (ORP) is organized to obtain funding to support scientifically meritorious research studies (clinical trials) at NCCN Member Institutions. Policies and standards for the program are set by the NCCN Investigator Steering Committee, comprised of senior research physicians appointed by each NCCN Member Institution. The NCCN ORP has received millions of dollars in research grants from major pharmaceutical companies to support investigator-initiated trials, which explore new venues of clinical investigation that answer important research questions. Studies evaluate innovative combinations and sequencing regimens of drugs, mechanisms of action of specific agents, drug resistance, or are directed toward exploring extended uses for specific agents.
Leading clinicians and investigators from NCCN Member Institutions evaluate promising new chemical entities or biological agents.
NCCN Oncology Research Program (ORP) – Click here if you are a clinician at an NCCN Member Institution and would like to:
View information for the NCCN Oncology Research Program for Industry.